Literature DB >> 21080240

Research advances in amyotrophic lateral sclerosis, 2009 to 2010.

Rebecca Traub1, Hiroshi Mitsumoto, Lewis P Rowland.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of upper and lower motor neurons that causes progressive weakness and death. The breadth of research in ALS continues to grow with exciting new discoveries in disease pathogenesis and potential future therapeutics. There is a growing list of identified mutations in familial ALS, including those in genes encoding TDP-43 and FUS/TLS, which are expanding our understanding of the role of RNA modulation in ALS pathogenesis. There is a greater appreciation for the role of glial cells in motor neuron disease. Mitochondrial dysfunction is also being shown to be critical for motor neuron degeneration. In addition to pharmacotherapy, there are promising early developments with therapeutic implications in the areas of RNA interference, stem cell therapies, viral vector-mediated gene therapy, and immunotherapy. With greater understanding of ALS pathogenesis and exciting new therapeutic technologies, there is hope for future progress in treating this disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21080240     DOI: 10.1007/s11910-010-0160-0

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  121 in total

1.  Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS.

Authors:  Cédric Raoul; Toufik Abbas-Terki; Jean-Charles Bensadoun; Sandrine Guillot; Georg Haase; Jolanta Szulc; Christopher E Henderson; Patrick Aebischer
Journal:  Nat Med       Date:  2005-03-13       Impact factor: 53.440

Review 2.  TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration.

Authors:  Clotilde Lagier-Tourenne; Magdalini Polymenidou; Don W Cleveland
Journal:  Hum Mol Genet       Date:  2010-04-15       Impact factor: 6.150

3.  A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2.

Authors:  S Hadano; C K Hand; H Osuga; Y Yanagisawa; A Otomo; R S Devon; N Miyamoto; J Showguchi-Miyata; Y Okada; R Singaraja; D A Figlewicz; T Kwiatkowski; B A Hosler; T Sagie; J Skaug; J Nasir; R H Brown; S W Scherer; G A Rouleau; M R Hayden; J E Ikeda
Journal:  Nat Genet       Date:  2001-10       Impact factor: 38.330

4.  Recombinant human granulocyte-colony stimulating factor administration for treating amyotrophic lateral sclerosis: A pilot study.

Authors:  Beatrice Nefussy; Irena Artamonov; Varda Deutsch; Ela Naparstek; Arnon Nagler; Vivian E Drory
Journal:  Amyotroph Lateral Scler       Date:  2010

5.  Reprogramming of human somatic cells to pluripotency with defined factors.

Authors:  In-Hyun Park; Rui Zhao; Jason A West; Akiko Yabuuchi; Hongguang Huo; Tan A Ince; Paul H Lerou; M William Lensch; George Q Daley
Journal:  Nature       Date:  2007-12-23       Impact factor: 49.962

6.  Directed differentiation of human-induced pluripotent stem cells generates active motor neurons.

Authors:  Saravanan Karumbayaram; Bennett G Novitch; Michaela Patterson; Joy A Umbach; Laura Richter; Anne Lindgren; Anne E Conway; Amander T Clark; Steve A Goldman; Kathrin Plath; Martina Wiedau-Pazos; Harley I Kornblum; William E Lowry
Journal:  Stem Cells       Date:  2009-04       Impact factor: 6.277

7.  Human neural stem cell grafts in the spinal cord of SOD1 transgenic rats: differentiation and structural integration into the segmental motor circuitry.

Authors:  Leyan Xu; David K Ryugo; Tan Pongstaporn; Karl Johe; Vassilis E Koliatsos
Journal:  J Comp Neurol       Date:  2009-06-01       Impact factor: 3.215

8.  Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1.

Authors:  L I Bruijn; M K Houseweart; S Kato; K L Anderson; S D Anderson; E Ohama; A G Reaume; R W Scott; D W Cleveland
Journal:  Science       Date:  1998-09-18       Impact factor: 47.728

9.  Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III.

Authors:  Petra Kaufmann; John L P Thompson; Gilberto Levy; Richard Buchsbaum; Jeremy Shefner; Lisa S Krivickas; Jonathan Katz; Yvonne Rollins; Richard J Barohn; Carlayne E Jackson; Ezgi Tiryaki; Catherine Lomen-Hoerth; Carmel Armon; Rup Tandan; Stacy A Rudnicki; Kourosh Rezania; Robert Sufit; Alan Pestronk; Steven P Novella; Terry Heiman-Patterson; Edward J Kasarskis; Erik P Pioro; Jacqueline Montes; Rachel Arbing; Darleen Vecchio; Alexandra Barsdorf; Hiroshi Mitsumoto; Bruce Levin
Journal:  Ann Neurol       Date:  2009-08       Impact factor: 10.422

Review 10.  Current hypotheses for the underlying biology of amyotrophic lateral sclerosis.

Authors:  Jeffrey D Rothstein
Journal:  Ann Neurol       Date:  2009-01       Impact factor: 10.422

View more
  15 in total

Review 1.  Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology, Management and Therapeutic Trials.

Authors:  Paul H Gordon
Journal:  Aging Dis       Date:  2013-10-01       Impact factor: 6.745

Review 2.  Role of mitochondria in mutant SOD1 linked amyotrophic lateral sclerosis.

Authors:  Wenzhi Tan; Piera Pasinelli; Davide Trotti
Journal:  Biochim Biophys Acta       Date:  2014-02-22

3.  Neural progenitors derived from human induced pluripotent stem cells survive and differentiate upon transplantation into a rat model of amyotrophic lateral sclerosis.

Authors:  Iuliana Ristea Popescu; Charles Nicaise; Song Liu; Grégoire Bisch; Sarah Knippenberg; Valery Daubie; Delphine Bohl; Roland Pochet
Journal:  Stem Cells Transl Med       Date:  2013-02-14       Impact factor: 6.940

4.  Senataxin mutations and amyotrophic lateral sclerosis.

Authors:  Michio Hirano; Catarina M Quinzii; Hiroshi Mitsumoto; Arthur P Hays; J Kirk Roberts; Patricia Richard; Lewis P Rowland
Journal:  Amyotroph Lateral Scler       Date:  2010-12-29

Review 5.  TDP-43 autoregulation: implications for disease.

Authors:  Mauricio Budini; Emanuele Buratti
Journal:  J Mol Neurosci       Date:  2011-06-18       Impact factor: 3.444

Review 6.  Research advances in gene therapy approaches for the treatment of amyotrophic lateral sclerosis.

Authors:  Monica Nizzardo; Chiara Simone; Marianna Falcone; Giulietta Riboldi; Federica Rizzo; Francesca Magri; Nereo Bresolin; Giacomo P Comi; Stefania Corti
Journal:  Cell Mol Life Sci       Date:  2011-11-18       Impact factor: 9.261

7.  Potential therapeutic drugs and methods for the treatment of amyotrophic lateral sclerosis.

Authors:  G Yacila; Y Sari
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

Review 8.  An overview of DNA repair in amyotrophic lateral sclerosis.

Authors:  Fabio Coppedè
Journal:  ScientificWorldJournal       Date:  2011-10-17

Review 9.  Protein misdirection inside and outside motor neurons in Amyotrophic Lateral Sclerosis (ALS): a possible clue for therapeutic strategies.

Authors:  Akemi Ido; Hidenao Fukuyama; Makoto Urushitani
Journal:  Int J Mol Sci       Date:  2011-10-19       Impact factor: 5.923

10.  The protective and therapeutic function of small heat shock proteins in neurological diseases.

Authors:  Sara E Brownell; Rachel A Becker; Lawrence Steinman
Journal:  Front Immunol       Date:  2012-05-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.